Drug Trial Radar · NCT07685808
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
360
Planned (sponsor's estimate)
Start
Jul 28, 2026
Primary completion
Jan 21, 2028
Study completion Jan 21, 2028
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Jul 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will test an experimental drug called olatorepatide ("study drug") to determine how safe and effective this drug is compared to placebo and how easily the body can accept this drug at different doses and dosing schedules without causing side effects, as well as how the drug is processed in the body by participants with overweight or obesity but do not have diabetes. The study is looking at: * What side effects the study drug might cause * How much study drug is in the blood at different times * How well the study drug works * What effects the study drug may have on the body at different dosing schedules * If the body makes antibodies to the study drug as this may cause the study drug to not work as well
Conditions
- Overweight or Obesity
Interventions
OlatorepatideDrug
Administered per the protocol
PlaceboDrug
Administered per the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to approximately 60 weeks
- Severity of TEAEsTime frame: Up to approximately 60 weeks
- Percent change in body weightTime frame: From baseline to week 52
Locations
22 sites in 1 country. Site status is shown where the registry gives one.
AMR Clinical - Mobile
Mobile, Alabama · Recruiting
Diablo Clinical Research - Flourish Research
Walnut Creek, California · Recruiting
Chase Medical Research
Waterbury, Connecticut · Recruiting
Alliance for Multispecialty Research (AMR) Clinical Miami
Doral, Florida · Recruiting
AMR Clinical - Fort Myers
Fort Myers, Florida · Recruiting
AGA Clinical Trials
Hialeah, Florida · Recruiting
Flourish Research, Nature Coast Clinical Research
Inverness, Florida · Recruiting
Flourish Research, Jacksonville Center for Clinical Research
Jacksonville, Florida · Recruiting
K2 Medical Research Maitland LLC, Main Office
Maitland, Florida · Recruiting
The IMA Group, IMA Clinical Research St. Petersburg
St. Petersburg, Florida · Recruiting
Charter Research LLC - The Villages
The Villages, Florida · Recruiting
Clinical Site Partners, LLC DBA Flourish Research
Winter Park, Florida · Recruiting
Charter Research LLC - Chicago
Chicago, Illinois · Recruiting
Flourish Research, Ravenswood Rheumatology
Chicago, Illinois · Recruiting
AMR Clinical - Chicago Oak Brook
Oak Brook, Illinois · Recruiting
AMR Clinical Wichita
Wichita, Kansas · Recruiting
AMR Clinical - Lexington
Lexington, Kentucky · Recruiting
Velocity Clinical Research - Omaha
Omaha, Nebraska · Recruiting
NYC Research Inc
New York, New York · Recruiting
Rochester Clinical Research
Rochester, New York · Recruiting
Tribe Clinical Research
Greenville, South Carolina · Recruiting
Flourish Research, Legacy Oaks Tower
San Antonio, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.